Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.33 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | GRK5 | P34947 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218448 | 0.77 | CYP2A6 (0.36) | ALDH1A1GRIA1CACNG8CYP1A2CYP2A6 | |
| SCHEMBL2974314 | 0.75 | CYP2A6 (0.36) | ALDH1A1CYP2A6LMNATSHRSRC | |
| SCHEMBL2962654 | 0.74 | ALDH1A1 (0.36) | PBRM1ALDH1A1PARP1 | |
| SCHEMBL5691260 | 0.69 | ADORA3 (0.38) | ALDH1A1TSHR | |
| SCHEMBL5600529 | 0.69 | PDCD1 (0.39) | ALDH1A1CYP2A6LMNA | |
| SCHEMBL11528492 | 0.67 | CYP2A6 (0.39) | ALDH1A1CYP1A2CYP2A6LMNATSHR | |
| SCHEMBL2471569 | 0.66 | TSHR (0.57) | ALDH1A1CES1CYP1A2CYP2A6RET | |
| SCHEMBL1047283 | 0.65 | PBRM1 (0.42) | PBRM1ALDH1A1CES1GRIA1CACNG8 | |
| SCHEMBL2970809 | 0.64 | — | — | |
| SCHEMBL23271726 | 0.64 | NSD2 (0.47) | CES1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | PBRM1 618/4885ALDH1A1 4332/4885CES1 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.